IIPR Short Sellers Retreat Before Earnings

IIPR enters today's earnings report having shed short interest at a pace far outside its own historical range. Short positions dropped nearly 17% over the past week, a move 3.5 standard deviations below the company's typical weekly change, leaving short interest at 12.7% of the free float. That is still a high absolute level for an industrial REIT, but the direction of travel is unusually sharp. The stock has responded, gaining 1.3% on the week to close at $54.40, broadly in line with its closest peers: PLD added 2.6% and STAG rose 3.3%, while ILPT fell 7.4%, making IIPR's move look middling rather than outsized. Borrow conditions remain loose: availability is running at 187%, meaning shares to lend comfortably exceed the existing short book, and cost to borrow is a modest 0.49%. Options traders are leaning constructively, with the put/call ratio at 0.49, near its 52-week low of 0.47 and well below the 20-day average of 0.70.

The short-covering tells a more interesting story when combined with the insider register. Executive Chairman Alan Gold made an open-market purchase of 40,000 shares on October 8 at $25.00, a $1 million cash outlay with no 10b5-1 plan attached. The stock has since moved well above that entry price to $54.40, though the gap between Gold's purchase price and the current price warrants a note: the trade was filed with the SEC and is presented as reported. That discretionary commitment from the company's founder sits alongside a 90-day net insider buying figure of roughly $996,000, with a director also adding shares in August. The ORTEX short score has eased from a recent high near 76 to 73 over the past ten days, consistent with the covering trend, though it remains in territory that ranks among the most shorted 2% of names in the ORTEX universe.

The analyst picture is divided. Stifel initiated coverage in October with a Buy rating and a $56.25 target, just above current prices. Piper Sandler maintained its Underweight and cut its target to $44 from $51 in the same week, keeping the stock $10 below where it trades today. The bull argument centres on improving funding costs for IIPR's IQHQ investment and the company's moves against illicit retail sales in cannabis tenants' locations. Bears point to a continued stream of tenant defaults, rising legal costs, and an open SEC investigation as structural headwinds that limit new supply coming to the company. BlackRock lifted its stake to 17.7% in its most recent filing, while the ORTEX dividend score ranks in the 97th percentile, suggesting yield-focused institutions still find the payout compelling despite the operational noise.

The print will test whether the tenant default cycle is stabilising enough to justify the recovery in the share price and the recent short-covering, or whether legal and regulatory costs have continued to erode the earnings base that supports both the dividend and the IQHQ thesis.